Oncology Target Articles & Analysis
28 news found
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be presented Bayer ...
ByBayer AG
Vividion will continue its mission to unlock high value, traditionally undruggable target biology with precision therapeutics for cancers and immune disorders. ...
ByBayer AG
“Antengene believes that cancer treatments involving the rational combination of immuno-oncology drugs and targeted therapies may offer the greatest opportunity for substantial advances in treatment outcomes for patients with cancer,” said Dr. ...
“I am impressed by the pipeline’s breadth of novel, first-in-class programs in oncology and immunology. These programs are nearly all targeting proteins the industry has previously viewed as undruggable, and indicate the potential to deliver enormous value to patients if successful. ...
ByBayer AG
Tavros to receive $17.5M upfront, up to $430.5M in milestone payments for initial four programs, and certain royalties over agreement term / Vividion will have rights to opt-in to up to five more targets for up to $482M in additional payments /Partnership to define novel drug targets and biomarkers, in addition to positioning existing compounds Tavros ...
ByBayer AG
” About SEngine Precision Medicine SEngine's mission is to deliver innovative precise targeted oncology drugs to individual patients by combining functional precision medicine and drug discovery. ...
"I’m impressed by the pipeline’s breadth of novel, first-in-class programs in oncology and immunology. These programs are nearly all targeting proteins the industry has previously viewed as undruggable and indicate the potential to deliver enormous value to patients if successful. ...
ByBayer AG
With all these strengths, we’ve been able to accelerate progress on our pipeline of novel, previously undruggable target programs this past year, and we look forward to the possibility of delivering multiple programs into the clinic starting next year." ...
ByBayer AG
Jubilant Therapeutics Inc. a clinical stage precision therapeutics Company advancing small molecule therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced data to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. ...
” Syed Kazmi, Chief Executive Officer, Jubilant Therapeutics Inc. said, “JBI-802, effectively modulates two validated oncology targets with similar affinity and quick on/off exposure kinetics, leading to synergistic anti-tumour activity with a reduced risk of thrombocytopenia. ...
Under the terms of the agreement, Genmab secures exclusive rights to Aclys antibodies (specific to an undisclosed target) for further research in conjunction with Genmab’s proprietary platforms. ...
The company is advancing a diversified pipeline of potential first-in-class/best-in-class antagonist and agonist therapies against high-value GPCR targets in oncology, immunology and other serious diseases. Orion is led by a highly experienced team with world leading expertise in GPCR pharmacology and peptide/protein engineering. ...
“In a matter of a few months, the team has been able to generate state of the art human antibody libraries against a whole host of immune-oncology targets. We are extremely excited to extend the system to human immunogenicity testing, and patient antibody ...
“In a matter of a few months, the team has been able to generate state of the art human antibody libraries against a whole host of immune-oncology targets. We are extremely excited to extend the system to human immunogenicity testing, and patient antibody ...
LOS ANGELES, CA, USA October 5, 2021 T-Cure Bioscience, Inc., a privately held company focused on developing autologous T Cell Receptor Therapy (TCR-T) products for the treatment of solid tumors, and Atlas Antibodies AB, a Swedish company commercializing PrecisA monoclonal antibodies (mAb) for oncology targets, announced today a collaborative agreement for the ...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Sep. 15, 2021-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group has received ...
Combines Exscientia’s leading AI-driven drug identification and design capabilities with GT Apeiron’s expertise in cyclin-dependent kinase (CDK) targets for oncology. Expands existing CDK7 drug discovery partnership with additional CDK targeting drugs Oxford & Shanghai – July 21st, 2021 – Exscientia, an AI-driven ...
-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance follows previous patents for methods in stimulating bone growth, promote controlled bone creation and repair of large segmental bone defects using ZetaMet™ Company’s intellectual property pipeline targets other ...
Atomwise and FutuRx have announced their first joint venture, A2i Therapeutics, with seed funding to leverage Atomwise’s AI platform to target a key protein involved in controlling the innate immune response and potentially a key immuno-oncology target. ...
Biosceptre is developing anti-cancer therapies – in particular, targeted therapeutics and immune-oncology products targeting most types of cancers, with the goal of bringing novel treatments to patients suffering from a wide range of malignancies. ...